



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Synthesis and evaluation of novel phosphoramidate prodrugs of 2'-methyl cytidine as inhibitors of hepatitis c virus NS5B polymerase

Monica Donghi^{a,*}, Barbara Attenni^a, Cristina Gardelli^a, Annalise Di Marco^a, Fabrizio Fiore^a, Claudio Giuliano^a, Ralph Laufer^a, Joseph F. Leone^b, Vincenzo Pucci^a, Michael Rowley^a, Frank Narjes^a

^a Department of Medicinal Chemistry, IRBM-MRL Rome, Via Pontina Km 30,600, 00040 Pomezia (Rome), Italy

^b Department of Preparative Chemistry & Separation, MRL Rahway, 126 E. Lincoln Avenue, PO BOX 2000, 07065-0900, NJ, USA

ARTICLE INFO

Article history:

Received 24 November 2008

Revised 9 January 2009

Accepted 14 January 2009

Available online 19 January 2009

Keywords:

Antiviral

HCV polymerase

Prodrugs

Phosphoramidates

Triphosphate

ABSTRACT

A variety of new prodrugs of 2'-methyl cytidine based on acyloxy ethylamino phosphoramidates have been synthesized and tested in vitro and in vivo for their biological activity. Compared with the parent drug a 10- to 20-fold increase in formation of nucleotide triphosphate in rat and human hepatocytes could be achieved.

© 2009 Elsevier Ltd. All rights reserved.

Hepatitis C virus (HCV) infection is a serious worldwide health problem affecting about 2% of the world population (WHO data).¹ While the early stages of the disease are typically asymptomatic, the majority of HCV infections progress to chronic infection, which is associated with an increased risk of cirrhosis, hepatocellular carcinoma, and liver failure. At present, the standard of care available to patients with chronic HCV infection is a combination of ribavirin and interferon-based therapies, which leads to a sustained virologic response in only about half of the patients treated.²

Efforts to discover more effective drugs to treat HCV-infected patients have focused on several possible targets, including the NS5B RNA-dependent RNA polymerase.³ 2'-Methyl cytidine⁴ has been shown to be an inhibitor of hepatitis virus C NS5B in cell culture.⁵ The 5'-triphosphate of this nucleoside is a potent active site inhibitor of hepatitis virus C polymerase.⁶ To enhance the bioavailability of 2'-methyl cytidine its 3'-valine ester has been prepared (NM283 = Valopicitabine **1**, Fig. 1)⁷ and a 1.2 log₁₀ viral reduction in HCV RNA was observed in patients upon dosing 800 mg qd.⁸ Its development has been stopped in phase II due to an unfavorable risk/benefit profile observed in clinical testing.^{3c}

For a variety of nucleosides with modified core structure (e.g., d4T or ara-C) a poor turnover to the nucleoside triphosphate (NTP) has been observed.^{9,10} In some cases this is attributed to the inability of the nucleoside kinase to catalyze the initial phos-

phorylation of the nucleoside to its monophosphate (NMP). To circumvent this problem, a suitable prodrug strategy would be one aimed at the delivery of the nucleoside monophosphate inside the target cell.¹¹

To this end, different approaches have been described in the literature. For example, Metabasis Therapeutics has reported cyclic cytochrome P450-3A-cleavable phosphate esters as liver targeted-prodrugs (so-called HepDirect prodrugs).¹² Furthermore, in the antiviral field, McGuigan and co-workers have described aryl-oxo phosphoramidates (incorporating an amino acid ester) as suitable pro-moieties, specifically to improve delivery of AZT and d4T (ProTide approach).¹³

In the search for HCV NS5B polymerase inhibitors we applied an analogous phosphoramidate approach to 2'-methyl cytidine.¹⁴ As a variation on the theme we also evaluated replacing the amino acid moiety with 2-aminoethanol. Although Imbach et al. reported this




Figure 1. Valopicitabine, NM283.

* Corresponding author. Fax: +39 06 91093225.

E-mail address: monica_donghi@merck.com (M. Donghi).




Figure 2. Acyloxyethylamino phosphoramidate prodrugs.

approach failed in their study on AZT derivatives,¹⁵ we were pleased to find that this strategy proved successful for our substrate. Herein we report the design, synthesis and biological evaluation of this novel 2'-Me-C-based series (Fig. 2).

The synthesis of the compounds was first performed under classical conditions by reaction of the unprotected nucleoside with a phosphoramidate chloride. This approach suffered from two major liabilities. The first is a physical issue related to the limited solubility of 2'-Me-C in organic solvents. The second derives from the poor yield in the reaction of the amino alcohol fragments with phenyl phosphorodichloridate. While the latter reacted smoothly with amino acid derivatives, only poor results were observed with amino alcohol derivatives. To circumvent these issues, a different route was developed. We found that the compounds could be conveniently prepared by first masking the secondary and tertiary alcohols on the nucleoside **2** as a 2',3'-acetonide (Scheme 1).

The resulting 5'-unprotected nucleoside **3** was then reacted with diphenyl phosphite to give the common intermediate **4**. This material was not isolated but subjected directly to an Atherton-Todd reaction with an *O*-acyl aminoethanol in the presence of tetrachloromethane.¹⁹ Careful deprotection of the phosphoramidates **5** afforded the desired prodrugs **6–19** in moderate overall yield (25% from nucleoside **2**). Separation of the two diastereoisomers was achieved for each derivative by reversed phase HPLC.

All compounds were routinely tested in the replicon assay.¹⁶ For representative compounds the formation of nucleoside triphosphate was assessed in screening mode in human and rat hepatocytes.¹⁷ Those compounds showing promising results were then profiled further.

In this report, we focus on the structure–activity relationship around the amino alcohol moiety, with the phenoxy functionality on the phosphoramidate remaining unvaried. In particular, initial studies were directed towards the preparation of a series of esters of unsubstituted ethanolamine ($R^1 = R^3 = H$).


Benzoyl and acetyl esters were prepared (examples **6–7**). These compounds exhibited encouraging improvements in cell-based activity, when compared with NM283. A significant step forward in terms of activity could then be made with the introduction of branched chain alkanolic esters **8–12** (Table 1). We found that not only small esters like those based on *iso*-butanoic acid were tolerated, but also longer chain esters like 2-ethylbutanoates and 2-propylpentanoates gave rise to very active compounds in the cell-based assay.

Substitution of the ethanolamine (**13–19**) was at best tolerated (**16b**) but still compatible with sub- μ M levels of inhibition in the replicon. However, simple *N*-methylation of the ethanolamine nitrogen ($R^4 = Me$, **20**) or exchanging the ethanolamine moiety with 3-hydroxy-prolinol (example **21**) completely abrogated activity.

Due to the chirality of the phosphorus all compounds were obtained as a mixture of diastereomers. These could be separated by HPLC or SFC. In most cases the second eluting diastereomer (e.g., **6b**, **9b**, **10b** and **16b**) turned out to be more active in the replicon assay than the first eluting product although in the end both diastereomers should yield the same nucleotide. Thus, a plausible hypothesis for pro-moiety activation would be via a stereoselective enzymatic first step (as for the McGuigan prodrug), whereby this stereochemical preference is then reflected in the replicon activity. The data reported in Table 1 refer to the second eluted diastereoisomer if not otherwise denoted.




For representative compounds the actual formation of nucleoside triphosphate from the prodrug was studied in rat and human hepatocytes. (Table 2). We were very pleased to observe that the replicon data could be associated with levels of NTP formation in comparison with the reference compound NM283. Compounds which had been found to be inactive in the replicon assay also did not give any appreciable level of NTP formation in hepatocytes (e.g., **20b**). It should be noted that the difference in activity between the first and the second eluting diastereomers observed in the replicon assay could not be fully explained by the hepatocyte assay data. However, the interspecies variability observed in the hepatocytes would be in agreement with an enzymatic activation. Taking into consideration the replicon and hepatocyte data we identified **10**, **11**, **12** and **16** as the most promising compounds.

Though **11** and **16** showed very satisfactory NTP formation in human hepatocytes, we considered the release of one equivalent of pivalic acid or tryptanol per molecule as a potential liability from a toxicity point of view,¹⁸ which led us to prefer compounds **10** and **12**.



Scheme 1. Preparation of new amino alcohol based arylphosphoramidate diester prodrugs.²⁰

Table 1
In vitro activity

Compound ^a	R1	R ²	R ³	R ⁴	Replicon (10% FCS) nM
NM283	–	–	–	–	7600 (<i>n</i> = 29)
6b	H	Ph	H	H	1960
7b	H	Me	H	H	1250
8b	H	cHep	H	H	1160
9 (1st)	H	3-Pentyl	H	H	2830
9b (2nd)	H	3-Pentyl	H	H	625
10a (1st)	H	4-Hep	H	H	450 (<i>n</i> = 4)
10b (2nd)	H	4-Hep	H	H	240 (<i>n</i> = 3)
11b	H	<i>t</i> Bu	H	H	226
12b	H	<i>i</i> Pr	H	H	182
13b	H	<i>i</i> Pr	Me	H	585
14b	Me	<i>i</i> Pr	H	H	542
15b	Bn	<i>i</i> Pr	H	H	921
16a (1st)		<i>i</i> Pr	H	H	717
16b (2nd)		<i>i</i> Pr	H	H	218
17b	<i>i</i> Bu	<i>t</i> Bu	H	H	1840
18b	Bn	<i>t</i> Bu	H	H	840
19b	<i>n</i> Bu	<i>t</i> Bu	H	H	659
20b	H	<i>i</i> Pr	H	Me	>10000
	–	–	–	–	>20000

R substituents refer to Figure 2.

^a b: Second eluting diastereomer if not noted otherwise.**Table 2**
Stability in human, dog and rat plasma over 120 min

Compound	NTP level ^a , (μM), 2 h (<i>n</i> = 2)		% of initial @ 120 min human/dog/rat
	Rat hepatocytes	Human hepatocytes	
NM283	<14	17 ± 10	
6b	41 ± 2	22 ± 0.1	0/98/41
7b	178 ± 64	48 ± 3	
10a	207 ± 190	36 ± 20	100/100/100
10b	133 ± 117	23 ± 2	100/100/100
11b	149 ± 57	120 ± 10	
12b		91 ± 13	0/95/15
14b	33 ± 8	26 ± 6	0/36/3
15b			83/90/0
16a	104 ± 20	62 ± 2	
16b	127 ± 6	128 ± 115	
18b	140 ± 21	191 ± 16	
19b	97 ± 29	33 ± 13	100/100/100
20b	<14	7 ± 1	

^a Incubated with 10 μM compound.

The stability in rat, dog and human plasma was determined for selected compounds (Table 2). When compared with other esters, the 2-propylpentanoate esters **10a** and **10b** exhibited good stability which was equaled only by the pivaloate ester **19**. For **10b** essentially no degradation was observed over 120 min while **12b** was not stable in human and rat plasma.

Kinetics of NTP formation of **10b** was further evaluated in hepatocytes from different species (Table 3) which confirmed the data obtained in screening mode.

To further profile the prodrugs, levels of NTP formation in rat liver after oral administration were measured. As illustrated for **6**, **10b** and **19**, in general NTP formation was very low (Table 4) with no improvement over NM283. To assess whether the disappointing liver levels might be related to poor intestinal absorption, the permeability of selected prodrugs across monolayers of Caco-2 cells was determined. Most compounds tested had very low cell permeability and displayed active efflux in the basolateral-apical direction (data not shown). Interestingly, although still poorly permeable, compound **19** did not show significant efflux (permeability coefficient = $1.40 \text{ cm}^2/\text{s} \times 10^6$; BA/AB ratio = 1.7). Thus, despite the presence of the undesirable pivaloate group, it was used as a model compound and dosed orally in rat. Unfortunately, as mentioned above, no improvement in NTP formation in liver was observed (Table 4), suggesting active efflux of the parent prodrug is not the only factor limiting liver NTP levels. At this point alternative routes of administration were evaluated and compound **10b** was dosed subcutaneously in rat (1.5 μmol/kg). Gratifyingly high liver NTP levels were observed at 6 h. This is in stark contrast to NM283 and demonstrated the potential of our strategy.

In conclusion, modifying McGuigan's approach we have identified a novel class of phosphoramidates starting from the known HCV polymerase inhibitor NM283. The prodrugs we identified have good po-

Table 3
NTP formation in hepatocytes (AUC_{0–4 h}, μM h)^a

Compound	Rat	Dog	Human	Rhesus	Rabbit
10b	2770	50	315	310	59

^a Incubated with 10 μM compound.**Table 4**
NTP levels in rat liver 6 h after oral dosing

Compound	R ¹	R ²	R ³	Rat liver NTP level, (nmol/g), 6 h	
				p.o. (30 μmol/kg)	s.c. (1.5 μmol/kg)
NM283	–	–	–	0.2	BLQ
6	H	Ph	H	0.3	
10b (2nd)	H	4-Hep	H	0.2	7.1
19	nBu	tBu	H	0.2	

BLQ = 0.1 nmol/g.

tency in the replicon assay. Furthermore, we were able to demonstrate that these new prodrugs form higher levels of triphosphate than NM283 in hepatocytes (human and preclinical species) and in rat liver after s.c. dosing. However, these promising results did not translate into the formation of high liver NTP levels in rat after p.o. dosing. Further studies addressing oral bioavailability, mechanism of pro-moiety activation and conversion to NTP ongoing.

Acknowledgments

The authors thank Renzo Bazzo for NMR studies, Alessandra Ceccacci, Nadia Gennari and Sergio Altamura for carrying out the biological assays, and Isabella Marucci and Antonella Cellucci for carrying out the NTP formation in hepatocytes.

References and notes

- Shepard, C. W.; Finelli, L.; Alter, M. *J. Lancet Infect. Dis.* **2005**, *5*, 558.
- Hughes, C. A.; Shafran, S. D. *Ann. Pharmacother.* **2006**, *40*, 74.
- (a) Beaulieu, P. L.; Tsantrizos, Y. S. *Curr. Opin. Investig. Drugs* **2004**, *5*, 838; (b) Koch, U.; Narjes, F. *Curr. Top. Med. Chem.* **2007**, *7*, 1302; (c) De Francesco, R.; Carfi, A. *Adv. Drug Deliv. Rev.* **2007**, *59*, 1242.
- (a) Walton, E. French patent application FR 1 581 1969 628.; (b) Walton, E. British patent application GB 1,209,654, 1970.; (c) Walton, E.; Jenkins, S. R.; Nutt, R. F.; Holly, F. W.; Nemes, M. *J. Med. Chem.* **1969**, *12*, 306.
- Leyssen, P.; De Lamballerie, X.; De Clercq, E.; Neyts, J. *Antivir. Res.* **2006**, *70*, 1 (A80).
- Carroll, S. S.; Tomassini, J. E.; Bosserman, M.; Getty, K.; Stahlhut, M. W.; Eldrup, A. B.; Bhat, B.; Hall, D.; Simcoe, A. L.; LaFemina, R.; Rutkowski, C. A.; Wolanski, B.; Yang, Z.; Migliaccio, G.; De Francesco, R.; Kuo, L. C.; MacCoss, M.; Olsen, D. B. *J. Biol. Chem.* **2003**, *278*, 11979.
- (a) Sommadossi, J. -P.; La Colla, P. International patent application WO 2004002422 A2, 2004.; (b) Pierra, C.; Benzaria, A.; Amador, A.; Moussa, A.; Mathieu, S.; Storer, R.; Gosselin, G. *Nucleos. Nucleot. Nucl. Acids* **2005**, *24*, 767; (c) Sorbera, L. A.; Castaner, J.; Leeson, P. A. *Drugs Fut.* **2006**, *31*, 320; (d) Pierra, C.; Amador, A.; Benzaria, S.; Cretton-Scott, E.; D'Amours, M.; Mao, J.; Mathieu, S.; Moussa, A.; Bridges, E. G.; Standing, D. N.; Sommadossi, J.-P.; Storer, R.; Gosselin, G. *J. Med. Chem.* **2006**, *49*, 6614.
- Toniutto, P.; Fabris, C.; Bitetto, D.; Fornasiere, E.; Rapetti, R.; Piri, M. *Curr. Opin. Investig. Drugs* **2007**, *2*, 150.
- (a) Allender, C. J.; Brain, K. R.; Ballaton, C.; Cahard, D.; Siddiqui, A.; McGuigan, C. *Analyt. Chim. Acta* **2001**, *435*, 107; (b) Gandhi, V.; Plunkett, W. *Clin. Pharmacokinet.* **2002**, *41*, 93; (c) Balzarini, J.; Herdewijn, P.; De Clercq, E. *J. Biol. Chem.* **1989**, *264*, 6127.
- (a) Balzarini, J.; Cooney, D. A.; Dalal, M.; Kang, G.-J.; Cupp, J. E.; De Clercq, E.; Broder, S.; Johns, D. G. *Mol. Pharmacol.* **1988**, *34*, 431; (b) Starnes, M. C.; Cheng, Y.-C. *J. Biol. Chem.* **1987**, *262*, 988; (c) Hao, Z.; Cooney, D. A.; Farquhar, D.; Perno, C. F.; Zhang, K.; Masood, R.; Wilson, Y.; Hartman, N. R.; Balzarini, J.; Johns, D. G. *Mol. Pharmacol.* **1990**, *37*, 157; (d) Johnson, M. A.; Ahluwalia, G.; Connelly, M. C.; Cooney, D. A.; Broder, S.; Johns, D. G.; Fridland, A. *J. Biol. Chem.* **1988**, *263*, 15354; (e) Johnson, M. A.; Fridland, A. *Mol. Pharmacol.* **1989**, *36*, 291.
- Périgaud, C.; Girardet J. -L.; Gosselin G.; Imbach J. -L., in: *Advances in Antiviral Drug Design*, vol. 2, JAI Press, London, 1996, p. 147.
- (a) Erion, M. D.; Reddy, K. R.; Robinson, E. D.; Ugarkar, B. G. United States Patent Application US 6,312,662 B1, 2001.; (b) Erion, M. D.; Reddy, K. R.; Boyer, S. H.; Matelich, M. C.; Gomez-Galeno, J.; Lemus, R. H.; Ugarkar, B. G.; Colby, T. J.; Schanzer, J.; Van Poelje, P. D. *J. Am. Chem. Soc.* **2004**, *126*, 5154; (c) Erion, M. D.;

- Van Poelje, P. D.; MacKenna, D. A.; Colby, T. J.; Montag, A. C.; Fujitaki, J. M.; Linemeyer, D. L.; Bullough, D. A. *J. Pharm. Exp. Ther.* **2005**, *312*, 554; (d) Reddy, K. R.; Boyer, S. H.; Erion, M. D. *Tetrahedron Lett.* **2005**, *46*, 4321; (e) Boyer, S. H.; Sun, Z.; Jiang, H.; Esterbrook, J.; Gomez-Galeno, J. E.; Craigo, W.; Reddy, K. R.; Ugarkar, B. G.; MacKenna, D. A.; Erion, M. D. *J. Med. Chem.* **2006**, *49*, 7711; (f) Erion, M. D.; Reddy, K. R.; MacCoss, M.; Olsen, D. B. International Patent Application WO 2007022073 A2, 2007.; (g) Hecker, S. J.; Reddy, K. R.; van Poelje, P. D.; Sun, Z.; Huang, W.; Varkhedkar, V.; Reddy, M. V.; Fujitaki, J. M.; Olsen, D. B.; Koeplinger, K. A.; Boyer, S. H.; Linemeyer, D. L.; MacCoss, M.; Erion, M. D. *J. Med. Chem.* **2007**, *50*, 3891.
- (a) McGuigan, C.; Cahard, D.; Sheeka, H. M.; De Clercq, E.; Balzarini, J. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 1183; (b) McGuigan, C.; Cahard, D.; Sheeka, H. M.; De Clercq, E.; Balzarini, J. *J. Med. Chem.* **1996**, *39*, 1748; (c) Balzarini, J.; Kruining, J.; Wedgwood, O.; Pannecouque, C.; Aquaro, S.; Perno, C. F.; Naesens, L.; Witvrouw, M.; Heitjink, R.; De Clercq, E.; McGuigan, C. *FEBS Lett.* **1997**, *410*, 324; (d) Siddiqui, A.; McGuigan, C.; Ballatore, C.; Srinivasan, S.; De Clercq, E.; Balzarini, J. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 381.
- Gardelli, C. et al., in preparation.
- Egron, D.; Lefebvre, I.; Périgaud, C.; Beltran, T.; Pompon, A.; Gosselin, G.; Aubertin, A.-M.; Imbach, J.-L. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1045.
- (a) Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R. *Science* **1999**, *285*, 110; (b) Bartenschlager, R.; Lohmann, V. *Antiviral Res.* **2001**, *52*, 1; (c) De Francesco, R.; Migliaccio, G.; Paonessa, G. International Patent Application WO 2002059321 A2, 2002.
- (a) Di Marco, A. et al., in preparation.; Human (pool of 10 donors) and rabbit hepatocytes were obtained from In Vitro Technologies (IVT), rhesus hepatocytes from Cambrex Biosciences while rat and dog hepatocytes were prepared as described in (b) Giuliano, C.; Fiore, F.; Di Marco, A.; Padron Velazquez, J.; Bishop, A.; Bonelli, F.; Gonzalez-Paz, O.; Marucci, I.; Harper, S.; Narjes, F.; Pacini, B.; Monteagudo, E.; Migliaccio, G.; Rowley, M.; Laufer, R. *Xenobiotica* **2005**, *35*, 1035.
- Brass, E. P. *Pharmacol. Rev.* **2002**, *54*, 589.
- (a) Atherton, F. R.; Openshaw, H. T.; Todd, A. R. *J. Chem. Soc.* **1945**, 660; (b) Gamble, M. P.; Smith, A. R. C.; Wills, M. *J. Org. Chem.* **1998**, *63*, 6068; (c) Pettit, G. R.; Anderson, C. R.; Gapud, E. J.; Jung, M. K.; Knight, J. C.; Hamel, E.; Pettit, R. K. *J. Nat. Prod.* **2005**, *68*, 1191.
- Synthetic and brief spectroscopic data on compound **10a,b**: Step 1: 2'-C-Methylcytidine (19.4 mmol) was dissolved in acetone (0.04 M) and *p*-toluenesulfonic acid (23.3 mmol, 1.2 equiv) and 2,2-dimethoxypropane (194 mmol, 10 equiv) were added. The resulting slurry was stirred for 24 h at RT. The solvent was evaporated, the residue was dissolved in MeOH and Amberlite A-26 (previously washed with 2 N NaOH and H₂O) was added. The resulting mixture was stirred for 2 h. The Amberlite was filtered off and the filtrate was evaporated. The resulting crude product was purified by column chromatography on silica gel (DCM/MeOH = 9:1) to give the desired product as a colorless powder. ¹H NMR (300 MHz, CD₃OD) δ 7.96 (d, *J* = 7.56 Hz, 1H), 6.18 (s, 1H), 5.90 (d, *J* = 7.56 Hz, 1H), 4.51–4.48 (m, 1H), 4.28–4.23 (m, 1H), 3.86 (dd, *J* = 3.04 and 12.12 Hz, 1H), 3.78 (dd, *J* = 3.52 and 12.12 Hz, 1H), 1.59 (s, 3H), 1.43 (s, 3H), 1.25 (s, 3H); Mass found for C₁₃H₁₉N₃O₅: MS (ES⁺) *m/z* 298.5 (M+H)⁺. Step 2: 2'-C-Methyl-2',3'-O-(1-methylethylidene)-cytidine (4.37 mmol) was dissolved in pyridine (1.45 M) in presence of molecular sieves. The resulting solution was cooled to 0 °C, diphenyl phosphite (80%, 5.68 mmol, 1.3 equiv) was added, and the mixture was stirred for 1 h at 0 °C. The solvent was evaporated and the residue dissolved in THF/CCl₄ (8:1, 0.12 M). The resulting solution was cooled to 0 °C and Et₃N (26.2 mmol, 6.0 equiv), and a solution of aminoethyl 2-propylpentanoate hydrochloride (5.68 mmol, 1.3 equiv) in *i*PrOH/THF (1:1, 8 ml) were added. The mixture was stirred for 30 min at 0 °C and then was quenched by the addition of water. The aqueous phase was extracted three times with EtOAc, the combined organic phases were washed with brine and dried over Na₂SO₄. All volatiles were evaporated in vacuo. The crude product was purified by column chromatography on silica gel (DCM/MeOH = 95:5) to give a colorless solid as mixture of diastereoisomers which was used without further characterization. Mass found for C₂₉H₄₃N₄O₉P: MS (ES⁺) *m/z* 623.6 (M+H)⁺. This material was dissolved in a solution of TFA/H₂O (8:2, 0.098 M) and the resulting solution was warmed to 30 °C and stirred for 20 min. The solvent was evaporated and the residue was dissolved in acetonitrile and purified by RP-HPLC (stationary phase: Phenomenex-Luna C₁₈, 5 μm, 21.20 × 250 mm. Mobile phase: acetonitrile/H₂O buffered with 5 mM AMBIC). The fractions containing the pure diastereoisomers were combined and lyophilized to afford the title compounds as colorless powders. First-eluting diastereoisomer **10a**¹ H NMR (300 MHz, CD₃OD) δ 7.71 (d, *J* = 7.6 Hz, 1H), 7.43–7.19 (m, 5H), 6.07 (s, 1H), 5.83 (d, *J* = 6.8 Hz, 1H), 4.58–4.5 (m, 1H), 4.47–4.34 (m, 1H), 4.18–4.05 (m, 3H), 3.74 (d, *J* = 9.1 Hz, 1H), 3.35–3.2 (m, 2H), 2.48–2.33 (m, 1H), 1.66–1.37 (m, 4H), 1.37–1.23 (m, 4H), 1.1 (s, 3H), 0.95–0.86 (m, 6H). ³¹P NMR: (300 MHz CD₃OD) δ: 5.45; Mass found for C₂₆H₃₉N₄O₉P: MS (ES⁺) *m/z* 583.4 (M+H)⁺. Second-eluting diastereoisomer **10b**¹ H NMR (300 MHz, CD₃OD) δ 7.71 (d, *J* = 7.4 Hz, 1H), 7.46–7.37 (m, 2H), 7.33–7.21 (m, 3H), 6.05 (s, 1H), 5.81 (d, *J* = 7.3 Hz, 1H), 4.56–4.50 (m, 1H), 4.44–4.34 (m, 1H), 4.18–4.05 (m, 3H), 3.76 (d, *J* = 9.1 Hz, 1H), 3.35–3.20 (m, 2H), 2.46–2.35 (m, 1H), 1.66–1.37 (m, 4H), 1.37–1.22 (m, 4H), 1.12 (s, 3H), 0.97–0.86 (m, 6H). ³¹P NMR: (300 MHz CD₃OD) δ: 5.52. Mass found for C₂₆H₃₉N₄O₉P: MS (ES⁺) *m/z* 583.4 (M+H)⁺.